iBio, Inc.
9 Innovation Way
Suite 100
Newark,
DE 19711
United States - Map
Phone: 302-355-0650
Fax: 302-356-1173
Website: http://www.ibioinc.com
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware. Key Statistics
| |
| | Pay | Exercised | Mr. Robert B. Kay ,
73
Exec. Chairman and Chief Exec. Officer | 300.00K | 0.00 | Mr. Robert L. Erwin ,
59
Pres | 237.00K | 0.00 | Mr. Jules A. M ,
66
Managing Director | 85.00K | N/A | Mr. Douglas J. Beck CPA,
52
Sr. Adviser | 165.00K | 0.00 | Mr. Scott Kain ,
35
Chief Financial Officer | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.05(11.90%) 1:01PM EDT - Nasdaq Real Time Price